Allergic contact dermatitis is an environmental health issue induced by chemicals. A set of alternative methods has been approved by the OECD to test potential skin sensitizers in vitro. The cell‐based assays represent early key events of the skin sensitization process. h‐CLAT, the human Cell Line Activation Test and U‐Sens using THP‐1 or U937 cells which respond to skin sensitizes with the expression of CD54 and CD86 (OECD 442E). The keratinocyte cell lines KeratinoSens® and LuSens express the Luciferase reporter gene upon activation of the Nrf2 stress pathway (OECD 442D).
These cell lines are provided by acCELLerate under license from Givaudan and BASF and are available either for cultivation or in the assay ready format. Assay Ready KeratinoSens Cells are as well included in the instaCELL KeratinoSens assay kit which has been qualified for multiplexing Nrf‐2 activation and toxicity. KeratinoSens and LuSens uses the Luciferase technology from Promega (U.S. Pat. No. 8008006 & EU Pat. No. 1341808B1) and may only be used under the terms of a limited use license.